Justin M Roberts
Overview
Explore the profile of Justin M Roberts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
2266
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Roberts J, San Martin R, Piyarathna D, MacKrell J, Rocha G, Dodge J, et al.
Oncotarget
. 2017 Jun;
8(27):44447-44464.
PMID: 28591703
Whether vitamin D is chemopreventive and/or has potential therapeutically in prostate cancer is unresolved. One confounding factor is that many prostate cancers express a TMPRSS2:ERG fusion gene whose expression is...
12.
Erb M, Scott T, Li B, Xie H, Paulk J, Seo H, et al.
Nature
. 2017 Feb;
543(7644):270-274.
PMID: 28241139
Recurrent chromosomal translocations producing a chimaeric MLL oncogene give rise to a highly aggressive acute leukaemia associated with poor clinical outcome. The preferential involvement of chromatin-associated factors as MLL fusion...
13.
Koblan L, Buckley D, Ott C, Fitzgerald M, Ember S, Zhu J, et al.
ChemMedChem
. 2016 Nov;
11(23):2575-2581.
PMID: 27862999
Evaluating the engagement of a small molecule ligand with a protein target in cells provides useful information for chemical probe optimization and pharmaceutical development. While several techniques exist that can...
14.
Tanaka M, Roberts J, Seo H, Souza A, Paulk J, Scott T, et al.
Nat Chem Biol
. 2016 Oct;
12(12):1089-1096.
PMID: 27775715
Cellular signaling is often propagated by multivalent interactions. Multivalency creates avidity, allowing stable biophysical recognition. Multivalency is an attractive strategy for achieving potent binding to protein targets, as the affinity...
15.
Roberts J, Tarafdar S, Joseph R, Andreotti A, Smithgall T, Engen J, et al.
Protein Sci
. 2016 Jan;
25(4):852-64.
PMID: 26808198
The Src Homology 3 (SH3) domain is an important regulatory domain found in many signaling proteins. X-ray crystallography and NMR structures of SH3 domains are generally conserved but other studies...
16.
Shu S, Lin C, He H, Witwicki R, Tabassum D, Roberts J, et al.
Nature
. 2016 Jan;
529(7586):413-417.
PMID: 26735014
Triple-negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. BET bromodomain inhibitors, which have shown efficacy in several models of cancer,...
17.
Roberts J, Bradner J
Curr Protoc Chem Biol
. 2015 Dec;
7(4):263-278.
PMID: 26629616
Bromodomain-containing proteins have emerged as desirable targets for anti-neoplastic and anti-inflammatory drug discovery. Toward the development of selective inhibitors of the BET family of bromodomains, we optimized bead-based assays to...
18.
Shafi A, Putluri V, Arnold J, Tsouko E, Maity S, Roberts J, et al.
Oncotarget
. 2015 Sep;
6(31):31997-2012.
PMID: 26378018
Metastatic prostate cancer (PCa) is primarily an androgen-dependent disease, which is treated with androgen deprivation therapy (ADT). Tumors usually develop resistance (castration-resistant PCa [CRPC]), but remain androgen receptor (AR) dependent....
19.
Tanaka M, Roberts J, Qi J, Bradner J
Pharm Pat Anal
. 2015 Jul;
4(4):261-84.
PMID: 26174566
Gene regulatory pathways comprise an emerging and active area of chemical probe discovery and investigational drug development. Emerging insights from cancer genome sequencing and chromatin biology have identified leveraged opportunities...
20.
Winter G, Buckley D, Paulk J, Roberts J, Souza A, Dhe-Paganon S, et al.
Science
. 2015 May;
348(6241):1376-81.
PMID: 25999370
The development of effective pharmacological inhibitors of multidomain scaffold proteins, notably transcription factors, is a particularly challenging problem. In part, this is because many small-molecule antagonists disrupt the activity of...